Welcome to our dedicated page for HALOZYME THERAPEUTICS SEC filings (Ticker: HALO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on HALOZYME THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into HALOZYME THERAPEUTICS's regulatory disclosures and financial reporting.
HALO officer Cortney Caudill filed an initial Form 3 reporting direct ownership of 7,674 shares and equity awards that can convert to common stock. The reported awards include stock options exercisable for 89,224 and 11,302 shares with exercise prices of $33.51 and $57.44, restricted stock units totaling 38,641 shares, and performance stock units totaling 11,483 shares. Altogether these positions represent approximately 150,650 underlying shares subject to vesting and exercise schedules tied to service and performance.
Halozyme Therapeutics, Inc. reported a leadership change, appointing Cortney Caudill as Senior Vice President, Chief Operating Officer effective October 1, 2025. She previously served as the company’s Senior Vice President, Chief Operations Officer since October 2023 and has more than two decades of operational experience at multiple life sciences companies, including Aeglea Biotherapeutics and several global biotechnology and pharmaceutical organizations.
Ms. Caudill will receive an initial annual base salary of $600,000 and has a 2025 bonus target equal to 50% of her base salary under the company’s executive incentive plans. In connection with her appointment, she will receive an equity award valued at $500,000, split equally between stock options and restricted stock units, which will vest over four years under Halozyme’s standard vesting schedule. The company states there are no family relationships or related-party transactions involving Ms. Caudill in her new role.
Halozyme Therapeutics entered into an Agreement and Plan of Merger to combine with Elektrofi, Inc. under which Halozyme's wholly owned subsidiary Erraid Merger Sub Inc. will merge into Elektrofi and Elektrofi will survive as a wholly owned subsidiary of Halozyme. The filing names Shareholder Representative Services LLC as the securityholders' representative. The disclosure describes the planned corporate combination but does not disclose financial terms, timing, or regulatory approvals in the provided excerpt.
Halozyme Therapeutics (HALO) Form 144 notice reports a proposed sale of 136,569 shares of common stock through J.P. Morgan Securities, with an aggregate market value reported as $10,015,970 and an approximate sale date of 10/01/2025 on NASDAQ. The filing shows the shares were acquired on 10/01/2025 via stock option exercise and paid in cash. Recent disclosed sales by the same person, Helen Torley, list nine separate transactions from 07/08/2025 through 09/04/2025, each of 20,000 shares, with gross proceeds shown for each trade.
Halozyme Therapeutics reported that it executed an Agreement and Plan of Merger with Elektrofi, Inc., with the combination to be implemented through Erraid Merger Sub Inc.
The merger agreement is dated September 30, 2025 and names Shareholder Representative Services LLC as shareholder representative. Halozyme issued a press release on October 1, 2025 describing this transaction, which is furnished as Exhibit 99.1 to this report.
Nicole LaBrosse, SVP and Chief Financial Officer of Halozyme Therapeutics (HALO), reported two open-market sales of common stock on 09/22/2025 executed under a Rule 10b5-1 trading plan adopted on June 11, 2025. The Form 4 shows a sale of 1,913 shares at a weighted-average price of $77.827 (prices in the range $77.34–$78.32) and a sale of 314 shares at a weighted-average price of $78.667 (range $78.37–$79.18).
Following the reported transactions, the beneficial ownership reported was 22,079 shares (direct). The filing was signed on behalf of the reporting person by an attorney-in-fact on 09/23/2025. The Form 4 discloses that the sales were effected by a broker pursuant to the 10b5-1 plan and provides weighted-average price ranges with an offer to furnish per-price quantities on request.
Halozyme Therapeutics insider Nicole LaBrosse executed option exercises and share sales under a Rule 10b5-1 plan on 09/10/2025. The reporting shows exercise of options to purchase 11,271 shares at $12.07 and 1,135 shares at $12.49, and brokered sales of 6,760 and 13,240 shares at weighted average prices in the $74.56–$76.30 range. After these transactions the reporting person beneficially owned 24,306 shares of common stock directly. The Form 4 discloses the trades were effected pursuant to a 10b5-1 trading plan adopted on June 11, 2025, and includes vesting histories for the reported options.
Form 144 notice filed for proposed sale of securities on NASDAQ totaling 22,227 shares with an aggregate market value of $1,690,807.89. The filing shows these shares represent part of the issuer's 116,966,000 outstanding shares and lists the approximate sale date as 09/10/2025.
The securities to be sold were acquired in two transactions: 12,406 shares from an option exercise on 09/10/2025 (paid in cash) and 9,821 shares as restricted stock units on 02/10/2023. The filer reports no sales of the issuer's securities in the past three months. Several standard filer and issuer identification fields in the notice are blank or not provided in the text.
Helen Torley, President and CEO and director of Halozyme Therapeutics (HALO), reported option exercises and share sales under a Rule 10b5-1 trading plan adopted March 21, 2025. She exercised multiple option blocks with an $8.11 exercise price on September 2-4, 2025, acquiring 60,000 shares from option exercises and receiving 60,000 option shares underlying those exercises. Concurrently she sold aggregated blocks of common stock on September 2-4, 2025 at weighted average prices reported in ranges between $71.99 and $75.44 per share. After these transactions, Ms. Torley beneficially owned 733,719 common shares and held remaining options exercisable into additional shares as reported.
Bernadette Connaughton, a director of Halozyme Therapeutics (HALO), reported sales of common stock on 09/02/2025 executed under a pre-established Rule 10b5-1 trading plan adopted on 05/29/2025. The Form 4 shows three sell transactions: 100 shares at $71.71, 2,977 shares at a weighted-average $73.618 (range $72.91–$73.89), and 923 shares at a weighted-average $74.111 (range $73.95–$74.38). After these disposals the reporting person beneficially owned 46,952 shares, held directly.